Balyasny Asset Management
MRSN

Balyasny Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Balyasny Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,000
Closed -$931K – 1564
2020
Q3 		$931K Buy
+2,000
New +$1.01M 0.01% 1014

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Balyasny Asset Management's MRSN Position: Q4 2024 in Review

Balyasny Asset Management sold out of Mersana Therapeutics (MRSN) in Q4 2024, closing a stake of 21,433 shares — an estimated $1.01M sold.

Balyasny Asset Management first reported a position in MRSN in Q2 2018 and held it in 14 quarters. The position peaked at $22.5M in Q4 2023. 128 funds tracked by Wall St. Rank hold MRSN as of Q4 2024.

  • Balyasny Asset Management reported no remaining Mersana Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 21,433 Mersana Therapeutics shares in Q4 2024, an estimated $1.01M.
  • Balyasny Asset Management first reported a position in Mersana Therapeutics in Q2 2018 and held it in 14 quarters.
  • Balyasny Asset Management's Mersana Therapeutics position peaked at $22.5M in Q4 2023.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.